de Boer SM, et al. - Among women with high-risk endometrial cancer who received adjuvant chemotherapy combined with radiotherapy vs pelvic radiotherapy alone in a multicenter randomized phase 3 PORTEC-3 trial, researchers did a post-hoc survival analysis and focused on the patterns of recurrence. Chemoradiotherapy vs radiotherapy alone was shown to provide significantly improved overall survival and failure-free survival in this updated analysis. Particularly for women with stage III or serous cancers, or both, discussing and recommending this treatment schedule was advised. In most patients with a relapse, the first site of recurrence was distant metastases, with occurrence reported in 78 of 330 women in the chemoradiotherapy group vs 98 of 330 in the radiotherapy-alone group. In both groups, isolated vaginal recurrence was identified as the first site of recurrence in one patient. In the chemoradiotherapy group vs in the radiotherapy-alone group, isolated pelvic recurrence was identified as the first site of recurrence in three and in four women, respectively.